Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

20 Jul 2022

Abstract excerpt

Abstract In neuroblastoma, MYCN amplification and 11q-deletion are important, although incomplete, markers of high-risk disease. It is therefore relevant to characterize additional alterations that can function as prognostic and/or predictive markers. Using SNP-microarrays, a group of neuroblastoma patients showing amplification of one or multiple 12q loci was identified. Two loci containing CDK4 and MDM2 were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35859155
DOI: 10.1038/s41598-022-16455-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroupPMID 35859155Read ↗

Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patientsSemantic proximity Read ↗

Molecular targeting therapies for neuroblastoma: Progress and challengesSemantic proximity Read ↗

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.Semantic proximity Read ↗

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastomaSemantic proximity Read ↗

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterationsSemantic proximity Read ↗

Chromosome Imbalances in Neuroblastoma—Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the FutureSemantic proximity Read ↗

Therapeutic targets for neuroblastomas.Semantic proximity Read ↗

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.